Literature DB >> 9627434

Behaviors in type II diabetes during contingency contracting.

E A Schlenk1, S Boehm.   

Abstract

The purpose of this study was to use existing data to describe the behaviors performed by 117 subjects with Type II diabetes who wrote contingency contracts with nurses. Data were analyzed from a larger, randomized clinical trial of contingency contracting to improve clinical outcomes. Subjects had a high rate of completion of behaviors in contingency contracts (M = 90.9%). Subjects performed a median of six behaviors overall and up to a median of three behaviors of each of the diabetic regimen behaviors. The majority performed diet (n = 68, 58.1%) and exercise (n = 69, 58.9%) behaviors, with only one third performing both behaviors (n = 40, 34.2%). The most frequent behavioral strategies used were breaking the behavior into steps and self-monitoring the behavior. The contingency contracting intervention should be modified to be more comprehensive with increased recognition of the time and effort required for concurrently changing diet and exercise.

Entities:  

Mesh:

Year:  1998        PMID: 9627434     DOI: 10.1016/s0897-1897(98)80218-8

Source DB:  PubMed          Journal:  Appl Nurs Res        ISSN: 0897-1897            Impact factor:   2.257


  3 in total

Review 1.  Patient contracts for chronic medical conditions: Scoping review.

Authors:  Erin Gallagher; Elizabeth Alvarez; Lin Jin; Dale Guenter; Lydia Hatcher; Andrea Furlan
Journal:  Can Fam Physician       Date:  2022-05       Impact factor: 3.025

2.  Knowledge and Outcome Measure of HbA1c Testing in Asian Indian Patients with Type 2 Diabetes from a Tertiary Care Center.

Authors:  Satyavani Kumpatla; Srikanth Medempudi; Deepa Manoharan; Vijay Viswanathan
Journal:  Indian J Community Med       Date:  2010-04

3.  The importance of community consultation and social support in adhering to an obesity reduction program: results from the Healthy Weights Initiative.

Authors:  Mark Lemstra; Marla R Rogers
Journal:  Patient Prefer Adherence       Date:  2015-10-15       Impact factor: 2.711

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.